XML 14 R4.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2019
Mar. 31, 2018
 [1]
Mar. 31, 2019
Mar. 31, 2018
 [1]
Total revenue $ 216.6 $ 183.1 $ 635.7 $ 549.8
Costs and expenses:        
Research and development expense 21.5 18.5 65.0 53.1
Change in the fair value of contingent consideration   (1.2) 1.4 (61.3)
Selling, general, and administrative expense 140.6 107.9 405.7 322.3
Total costs and expenses 210.7 169.3 622.5 445.5
Operating income 5.9 13.8 13.2 104.3
Other income (expense):        
Interest income 0.7 0.5 2.3 1.2
Interest expense (3.2) (0.5) (8.8) (2.2)
Other (0.1) (0.5) 1.0 (1.3)
Total other expense: (2.6) (0.5) (5.5) (2.3)
Income before income tax 3.3 13.3 7.7 102.0
Income tax provision (3.6) 4.3 (1.0) (16.7)
Net income 6.9 9.0 8.7 118.7
Net loss attributable to non-controlling interest   (0.1) (0.1) (0.2)
Net income attributable to Myriad Genetics, Inc. stockholders $ 6.9 $ 9.1 $ 8.8 $ 118.9
Earnings per share:        
Basic $ 0.09 $ 0.13 $ 0.12 $ 1.72
Diluted $ 0.09 $ 0.13 $ 0.12 $ 1.66
Weighted average shares outstanding:        
Basic 73.3 69.8 73.5 69.2
Diluted 74.9 72.4 76.4 71.7
Molecular Diagnostic Testing [Member]        
Total revenue $ 200.5 $ 169.3 $ 592.5 $ 509.7
Costs and expenses:        
Total costs and expenses 40.3 36.8 126.6 110.7
Pharmaceutical and Clinical Services [Member]        
Total revenue 16.1 13.8 43.2 40.1
Costs and expenses:        
Total costs and expenses $ 8.3 $ 7.3 $ 23.8 $ 20.7
[1] Amounts adjusted due to the adoption of Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606). See Note 1 to the financial statements contained in Part I, Item 1 of this report for additional information.